SK42899A3 - 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds - Google Patents
3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds Download PDFInfo
- Publication number
- SK42899A3 SK42899A3 SK428-99A SK42899A SK42899A3 SK 42899 A3 SK42899 A3 SK 42899A3 SK 42899 A SK42899 A SK 42899A SK 42899 A3 SK42899 A3 SK 42899A3
- Authority
- SK
- Slovakia
- Prior art keywords
- substituted
- alkoxyisoxazol
- alkyl
- acid derivatives
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK109296 | 1996-10-04 | ||
PCT/DK1997/000426 WO1998015542A1 (en) | 1996-10-04 | 1997-10-03 | 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SK42899A3 true SK42899A3 (en) | 1999-08-06 |
Family
ID=8100908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK428-99A SK42899A3 (en) | 1996-10-04 | 1997-10-03 | 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds |
Country Status (26)
Country | Link |
---|---|
US (1) | US6200999B1 (no) |
EP (1) | EP0934286B1 (no) |
JP (1) | JP2001501630A (no) |
KR (1) | KR20000048908A (no) |
CN (1) | CN1238766A (no) |
AR (1) | AR008880A1 (no) |
AT (1) | ATE230734T1 (no) |
AU (1) | AU733004B2 (no) |
BG (1) | BG103348A (no) |
BR (1) | BR9712198A (no) |
CA (1) | CA2268028C (no) |
CZ (1) | CZ116899A3 (no) |
DE (1) | DE69718338T2 (no) |
EA (1) | EA001625B1 (no) |
ES (1) | ES2189978T3 (no) |
HU (1) | HUP0000084A3 (no) |
IL (1) | IL129135A0 (no) |
IS (1) | IS5009A (no) |
NO (1) | NO312961B1 (no) |
NZ (1) | NZ334798A (no) |
PL (1) | PL332553A1 (no) |
SK (1) | SK42899A3 (no) |
TR (1) | TR199900724T2 (no) |
UA (1) | UA52698C2 (no) |
WO (1) | WO1998015542A1 (no) |
ZA (1) | ZA978877B (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA73749C2 (en) * | 1999-11-01 | 2005-09-15 | Diarylenines | |
ZA200301696B (en) * | 2000-09-15 | 2004-04-28 | Vertex Pharma | Isoxazoles and their use as inhibitors of erk. |
US20040106794A1 (en) * | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
UA78529C2 (en) | 2001-10-10 | 2007-04-10 | Wyeth Corp | Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain |
US20040152694A1 (en) * | 2003-02-04 | 2004-08-05 | Istvan Kurucz | Methods and compositions for treating inflammatory disorders of the airways |
US7253153B2 (en) | 2003-04-09 | 2007-08-07 | Wyeth | Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof |
TW200514775A (en) | 2003-10-22 | 2005-05-01 | Wyeth Corp | Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof |
AU2006301376A1 (en) * | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
WO2009092324A1 (en) * | 2008-01-16 | 2009-07-30 | Hong Kong University Of Science And Technology | Oxazolidine derivatives as nmda antagonists |
EP2338492A1 (en) | 2009-12-24 | 2011-06-29 | Universidad del Pais Vasco | Methods and compositions for the treatment of alzheimer |
TW201609719A (zh) * | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物 |
CN108473431B (zh) * | 2016-01-21 | 2021-08-10 | 阿格罗-金正株式会社 | 2-氨基烟酸苄酯衍生物的制造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0456519T3 (da) | 1990-05-11 | 1994-11-07 | Sankyo Co | Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse |
DE69325662T2 (de) | 1992-10-23 | 2000-02-10 | Merck Sharp & Dohme Ltd., Hoddesdon | Dopamin rezeptor subtyp liganden |
DK124393D0 (da) * | 1993-11-03 | 1993-11-03 | Lundbeck & Co As H | Compounds |
-
1997
- 1997-03-10 UA UA99042300A patent/UA52698C2/uk unknown
- 1997-10-03 IL IL12913597A patent/IL129135A0/xx unknown
- 1997-10-03 KR KR1019990702938A patent/KR20000048908A/ko not_active Application Discontinuation
- 1997-10-03 EP EP97942821A patent/EP0934286B1/en not_active Expired - Lifetime
- 1997-10-03 BR BR9712198-3A patent/BR9712198A/pt unknown
- 1997-10-03 ES ES97942821T patent/ES2189978T3/es not_active Expired - Lifetime
- 1997-10-03 CA CA002268028A patent/CA2268028C/en not_active Expired - Fee Related
- 1997-10-03 TR TR1999/00724T patent/TR199900724T2/xx unknown
- 1997-10-03 AU AU44517/97A patent/AU733004B2/en not_active Ceased
- 1997-10-03 AT AT97942821T patent/ATE230734T1/de not_active IP Right Cessation
- 1997-10-03 EA EA199900358A patent/EA001625B1/ru not_active IP Right Cessation
- 1997-10-03 PL PL97332553A patent/PL332553A1/xx unknown
- 1997-10-03 SK SK428-99A patent/SK42899A3/sk unknown
- 1997-10-03 CZ CZ991168A patent/CZ116899A3/cs unknown
- 1997-10-03 DE DE69718338T patent/DE69718338T2/de not_active Expired - Fee Related
- 1997-10-03 JP JP10517096A patent/JP2001501630A/ja active Pending
- 1997-10-03 US US09/269,356 patent/US6200999B1/en not_active Expired - Fee Related
- 1997-10-03 CN CN97180167A patent/CN1238766A/zh active Pending
- 1997-10-03 ZA ZA9708877A patent/ZA978877B/xx unknown
- 1997-10-03 AR ARP970104586A patent/AR008880A1/es not_active Application Discontinuation
- 1997-10-03 HU HU0000084A patent/HUP0000084A3/hu unknown
- 1997-10-03 NZ NZ334798A patent/NZ334798A/en unknown
- 1997-10-03 WO PCT/DK1997/000426 patent/WO1998015542A1/en not_active Application Discontinuation
-
1999
- 1999-03-20 BG BG103348A patent/BG103348A/xx unknown
- 1999-03-23 IS IS5009A patent/IS5009A/is unknown
- 1999-03-30 NO NO19991561A patent/NO312961B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0934286B1 (en) | 2003-01-08 |
DE69718338T2 (de) | 2003-10-16 |
ATE230734T1 (de) | 2003-01-15 |
KR20000048908A (ko) | 2000-07-25 |
NO991561L (no) | 1999-06-04 |
AU733004B2 (en) | 2001-05-03 |
HUP0000084A3 (en) | 2001-12-28 |
CA2268028A1 (en) | 1998-04-16 |
NO312961B1 (no) | 2002-07-22 |
ZA978877B (en) | 1998-04-17 |
CN1238766A (zh) | 1999-12-15 |
AR008880A1 (es) | 2000-02-23 |
EA199900358A1 (ru) | 1999-10-28 |
IL129135A0 (en) | 2000-02-17 |
DE69718338D1 (de) | 2003-02-13 |
ES2189978T3 (es) | 2003-07-16 |
BG103348A (en) | 1999-11-30 |
PL332553A1 (en) | 1999-09-13 |
CA2268028C (en) | 2003-03-18 |
UA52698C2 (uk) | 2003-01-15 |
NZ334798A (en) | 2000-06-23 |
IS5009A (is) | 1999-03-23 |
AU4451797A (en) | 1998-05-05 |
TR199900724T2 (xx) | 1999-06-21 |
EP0934286A1 (en) | 1999-08-11 |
NO991561D0 (no) | 1999-03-30 |
JP2001501630A (ja) | 2001-02-06 |
WO1998015542A1 (en) | 1998-04-16 |
BR9712198A (pt) | 1999-08-31 |
HUP0000084A2 (hu) | 2000-06-28 |
EA001625B1 (ru) | 2001-06-25 |
CZ116899A3 (cs) | 1999-09-15 |
US6200999B1 (en) | 2001-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4430941B2 (ja) | Edg受容体作動薬 | |
JPH11509175A (ja) | N−ヘテロアリールピリジンスルホンアミド誘導体およびエンドテリンアンタゴニストとしてのそれらの使用 | |
USRE38200E1 (en) | Indole-2,3-dione-3-oxime derivatives | |
KR20210024574A (ko) | 세포 괴사 억제제 및 이의 제조 방법과 용도 | |
SK42899A3 (en) | 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds | |
JPH04234857A (ja) | 3,5−ジ置換2−イソキサゾリンおよびイソキサゾール、それらの製法およびそれらを含有する薬学的組成物 | |
AU2001264116B2 (en) | Amidine derivatives as selective antagonists of NMDA receptors | |
US10117864B2 (en) | Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof | |
EP1167369A1 (en) | Novel thiazolobenzimidazole derivatives | |
JP2009523711A (ja) | 新規環状置換フロピリミジン誘導体および心臓血管疾患を処置するためのその使用 | |
US6239128B1 (en) | Indole-2,3-dione-3-oxime derivatives for therapeutic use | |
RU2138488C1 (ru) | Соединения 2-аминокарбоновой кислоты, замещенной 5-арилизоксазол-4-илом, и фармацевтическая композиция на их основе | |
JP2650739B2 (ja) | 分割化アミノピロリジン神経防護剤 | |
US11149018B2 (en) | Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
US11136296B2 (en) | Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
WO2017153231A1 (de) | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung | |
JP2837318B2 (ja) | アンジオテンシンii拮抗性ピリジン誘導体 |